Navigation Links
Quest Diagnostics Again Named to FORTUNE Magazine's 'World's Most Admired Companies' List
Date:3/3/2009

Ranks second overall and first for long-term investment and social responsibility in industry category

MADISON, N.J., March 3 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, has again been named to FORTUNE magazine's list of the World's Most Admired Companies. Quest Diagnostics ranked second in the "Health Care" category of "Pharmacy and Other Services." The 2009 ranking is the second consecutive year that the company has been included on FORTUNE's Most Admired Companies list. The company advanced to second place from third in 2008. The new World's Most Admired Companies list is widely considered the definitive report card on corporate reputations.

"This prestigious recognition reflects the dedicated efforts of our 43,000 employees to put patients first and provide superior diagnostic services," said Surya N. Mohapatra, Ph.D., Chairman and CEO of Quest Diagnostics. "We are particularly gratified to have ranked number one in our industry category for long-term investment, which demonstrates support for our strategy and vision."

FORTUNE's list of the World's Most Admired Companies is based on surveys of more than 4,000 executives, directors and securities analysts of companies they admire most in their industry based on nine criteria: innovation, people management, use of corporate assets, quality of management; social responsibility; financial soundness, long-term investment, quality of products and services, and global competitiveness. For 2009, FORTUNE published one list rather than separate World's Most Admired and America's Most Admired lists in order to better represent the competitive landscape faced by today's companies.

The full list and related stories appear in the March 16 issue of FORTUN
'/>"/>

SOURCE Quest Diagnostics Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. FRC Action Questions President Obamas Choice of Gov. Sebelius for HHS
2. Presidents 2010 Budget Request Strongly Supports VA Programs
3. An Athletes First Question: Doc, When Can I Return?
4. Six Questions Consumers Should Ask About Genetic Tests
5. Virtual studies answer real questions
6. Findings raise new questions about evolution of hormones in mammals
7. Charleston Conducts Evaluation of an Opioid Symptoms Questionnaire
8. C4CC Education Fund Launches Discussion Forum for Consumers With Health Insurance Questions
9. SurgiQuest Announces FDA Approval for Smoke & Plume Evacuation for AirSeal Dynamic Pressure System(TM)
10. Study questions effectiveness of $80 million per year brain exercise products industry
11. ANA and ISONG Co-Publish Genetics and Ethics in Health Care: New Questions in the Age of Genomic Health
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 2Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 3Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 4Vivakor Announces New Acquisition Strategy 2Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lee's Pharmaceuticals 2YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 1YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 2YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 3YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 4YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 5YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 6U S FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U S Bridge to Transplant Clinical Trial 5241 1U S FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U S Bridge to Transplant Clinical Trial 5241 2U S FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U S Bridge to Transplant Clinical Trial 5241 3New Hampshire Rx Card Launching Statewide 5239 1New Hampshire Rx Card Launching Statewide 5239 2